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Abstract
Background: A subset of rheumatoid arthritis (RA) patients have detectable antibodies directed against the peptidyl-
arginine deiminase (PAD) enzyme isoforms 3 and 4. Anti-PAD3/4 cross-reactive antibodies (anti-PAD3/4XR) have been
shown to lower the calcium threshold required for PAD4 activation, an effect potentially relevant to the pathogenesis of RA-
associated interstitial lung disease (ILD).
Methods: RA patients underwent multi-detector computed tomography (MDCT) of the chest with interpretation by a
pulmonary radiologist for ILD features. A semi-quantitative ILD Score (range 0–32) was calculated. Concurrent serum
samples were assessed for antibodies against PAD by immunoprecipitation with radiolabeled PAD3 and PAD4.
Results: Among the 176 RA patients studied, any ILD was observed in 58 (33%) and anti-PAD3/4XR was detected in 19
(11%). The frequency of any ILD among those with anti-PAD3/4XR was 68% vs. 29% among those with no anti-PAD (crude
OR= 5.39; p = 0.002) and vs. 27% among those with anti-PAD4 that was not cross-reactive with PAD3 (crude OR= 5.74;
p = 0.001). Both associations were stronger after adjustment for relevant confounders (adjusted ORs = 7.22 and 6.61,
respectively; both p-values,0.01). Among ever smokers with anti-PAD3/4XR, the adjusted frequency of any ILD was 93% vs.
17% for never smokers without the antibody (adjusted OR= 61.4; p = 0.001, p-value for the interaction of smoking with anti-
PAD3/4XR,0.05).
Conclusions: The prevalence and extent of ILD was markedly higher among RA patients with anti-PAD3/4 cross-reactive
antibodies, even after accounting for relevant confounders, particularly among ever smokers. These findings may suggest
etiopathologic mechanisms of RA-ILD, and their clinical utility for predicting ILD warrants additional study.
Citation: Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, et al. (2014) Association of Cross-Reactive Antibodies Targeting Peptidyl-Arginine Deiminase 3 and 4
with Rheumatoid Arthritis-Associated Interstitial Lung Disease. PLoS ONE 9(6): e98794. doi:10.1371/journal.pone.0098794
Editor: Masataka Kuwana, Keio University School of Medicine, Japan
Received February 6, 2014; Accepted May 7, 2014; Published June 5, 2014
Copyright:  2014 Giles et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR050026-
01 (JMB), grant support from the Stabler Family Foundation, the Mackley Fund from Sibley Memorial Hospital, and NIH grant P30 AR053503 (AR, ED, FA), and
awards from the American College of Rheumatology Research and Education Foundation Within-Our-Reach Campaign (SKD, JTG). Additional support was
provided by the Johns Hopkins Bayview Medical Center General Clinical Research Center (Grant Number M01RR02719). The funders had no role in the study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests. Antony Rosen, Erika Darrah, Felipe Andrade and Jon T. Giles are authors on a provisional patent
application entitled ‘‘Human autoantibodies specific for PAD3 which are crossreactive with PAD4 and their use in the diagnosis and treatment of rheumatoid
arthritis’’ (P12072-01) that was filed with the United States Patent and Trademark Office. There are no restrictions on sharing of study material and/or data related




Clinically significant interstitial lung disease (ILD) is observed in
8–15% of individuals with rheumatoid arthritis (RA) and is a
major source of morbidity and mortality [1–4]. Prognosis after the
development of symptomatic RA-ILD is poor, with life expectancy
averaging only 2.6 years [1]. Progressive decline in lung function,
supplemental oxygen requirement, physical disability, secondary
pulmonary hypertension with right heart failure, and need for lung
transplantation are severe consequences [4,5]. Subclinical RA-
ILD is even more common, with radiographic ILD, as assessed
using computed tomography (CT), observed in up to 50% of RA
patients [6–8]. Although limited by the lack of clinical trials, there
are, to date, no pharmacotherapies proven to be effective in
altering the natural history of RA-ILD once symptoms have
developed [9], and robust biomarkers for predicting those at risk
for RA-ILD are lacking.
The pathogenesis of RA-ILD is poorly understood. One
mechanistic possibility involves the presence and consequences
of pulmonary citrullinated proteins. Citrullination is the post-
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translational modification of arginine residues to citrulline
catalyzed by the peptidyl-arginine deiminase (PAD) enzymes
[10]. Citrullination results in a net loss of charge and a more
hydrophobic protein, with implications for protein folding and
tertiary structure [11,12]. Citrullinated proteins are present in lung
tissue of patients with RA-ILD [13], idiopathic pulmonary fibrosis
(IPF), and even broncho-alveolar lavage fluid from heavy smokers
[14]. Repertoire expansion of antibodies against citrullinated
protein antigens (ACPA) is associated with RA susceptibility [15],
articular damage [16], and the presence and extent of radio-
graphic RA-ILD [7], suggesting that citrullination of lung proteins
and/or pathogenic ACPA may contribute to the pathogenesis of
RA-ILD, perhaps via interfering with the normal functioning of
targeted proteins or via pathologic antigen/antibody interactions.
PAD function is dependent on calcium, with maximal PAD
function requiring 5–10 mM concentrations. This threshold is
difficult to achieve in vivo and perhaps serves as a physiologic
regulator of citrullination. Recently, we reported the discovery of
an antibody targeting an epitope common to both PADs 3 and 4
that was highly specific for RA and was strongly associated with
progression of radiographic erosions [17]. Adding purified IgG
from patients with PAD3/4 cross-reactive antibodies (anti-PAD3/
4XR) to PAD4 resulted in increased in vitro histone citrullination at
physiologic concentrations of calcium, an effect not observed with
the addition of anti-PAD4 that was not cross-reactive with PAD3.
Accordingly, we hypothesized that RA patients with anti-PAD3/
4XR would demonstrate a greater prevalence and extent of RA
comorbidities in which tissue citrullination and/or pathogenic
ACPA may play an etiopathologic role, such as RA-ILD.
Methods
Study Participants
Participants were enrolled in ESCAPE RA (Evaluation of
Subclinical Cardiovascular disease And Predictors of Events in
Rheumatoid Arthritis), a prospective cohort study investigating
subclinical cardiovascular disease in RA described previously
[18,19]. Participants met 1987 RA classification criteria [20], had
RA$6 months from diagnosis, and were 45–84 years of age
without known prior pre-specified cardiovascular events. All
patients provided written informed consent prior to enrollment,
and the study and consent procedures were approved by the
Institutional Review Board (IRB) of the Johns Hopkins Hospital.
Ongoing analyses were approved by the Columbia University
Medical Center IRB. Enrollment occurred between October 2004
and May 2006.
Outcomes
Pulmonary outcomes. As described previously [18], cardiac
multi-detector row CT (MDCT) scans were obtained using
standard methods [21] with 3 mm thickness on a Toshiba
Aquilion 64 scanner. With cardiac MDCT, only lung parenchyma
from the level of the carina to the lung bases was included. The
validity of cardiac MDCT for pulmonary parenchymal disease has
been evaluated, with correlation.90% compared to high-resolu-
tion CT [22]. Scans were assessable in 176 of the 195 enrolled
participants (91%) by an expert pulmonary radiologist using a
previously described standardized method [23] and blinded to
clinical characteristics. Characteristics of the subgroup with
assessable scans did not differ from those of the full cohort (data
not shown). An ILD score (ILDS) was calculated based on the
presence and extent of ILD features [i.e. ground glass opacification
(GGO), reticulation (R), honeycombing (HC), and traction
bronchiectasis (TB)] using a semi-quantitative scale (0 = none,
1 = 1–25%, 2= 26–50%, 3= 51–75%, 4= 76–100%) with a
maximum total score possible of 32. Intra-observer concordance
for detecting no ILD was 90%, and 100% for ILDS$3.
Pulmonary function testing (PFT), consisting of spirometry and
assessment of carbon monoxide diffusing capacity (DLCo), was
performed according to American Thoracic Society guidelines
[24] at the second study visit, occurring a mean 6 standard
deviation of 2163 months post-baseline. Any restriction and
impaired diffusion were both defined as#79% of predicted for
forced vital capacity (FVC) and DLCo, respectively.
Measurement of circulating anti-PAD3/4XR. Antibodies
against PADs 3 and 4 were assessed as previously described [17].
Briefly, patient serum was added to [35S] Methionine labeled
in vitro transcribed and translated PAD3 or PAD4. Radiolabeled
immune complexes were incubated with Protein A beads and
subsequently washed and boiled in SDS sample buffer. Radiog-
raphy was used to visualize immunoprecipitated proteins separat-
ed by gel electrophoresis. Proteins were quantified using densi-
tometry and levels normalized a standard sample with the high
titer anti-PAD3/4XR antibodies. Seropositivity was defined at $
0.01 of the normalized value, as none of the non-RA control
samples (from healthy controls and patients with psoriatic arthritis)
had levels above this cutpoint [17].
Other measures. Demographics, current and past smoking,
and medical and RA disease history were assessed by patient self-
report. Forty-four joints were examined for swelling and tender-
ness by a single trained assessor and RA disease activity calculated
using the Disease Activity Score for 28 joints with CRP (DAS28-
CRP) [25]. The Stanford Health Assessment Questionnaire
(HAQ) [26] was used to assess disability. Current and past use
of glucocorticoids, biologic and non-biologic disease modifying
anti-rheumatic drugs (DMARDs) was queried by detailed exam-
iner-administered questionnaires. Radiographs of the hands and
feet were scored using the van der Heijde modification of the
Sharp method (SHS) [27] by a single experienced reader blinded
to patient characteristics.
Other laboratory assessments. C-reactive protein (CRP)
was measured by nephelometry (Dade Behring Inc., Deerfield, IL).
RF was assessed by ELISA, with seropositivity defined at or above
a level of 40 units. Serum samples obtained concurrently with CT
scanning were assessed for anti-CCP (CCP2) using a commercial
kit. The presence of shared epitope alleles in exon 2 of HLA-
DRB1 was determined as previously described [19].
Statistical Methods
After exploring the distributions of all variables, group-wise
differences in normally distributed continuous variables were
compared using t-tests, in non-normally distributed continuous
variables using the Kruskal-Wallis test, and in categorical variables
using the chi-square goodness-of-fit or Fisher’s exact test, as
appropriate. The associations of PAD antibody status with
dichotomous pulmonary outcomes were explored using ordinary
logistic regression, and for continuous pulmonary outcomes with
linear regression, with variables transformed to normality as
required. Multivariable (MV) regression models were constructed,
with potential confounders included that were associated with the
primary exposure variable in univariate analyses at the p,0.20
significance level, to allow for residual confounding. Non-
contributory covariates were excluded using the Likelihood-Ratio
Test for nested models or Akaike’s Information Criterion, as
appropriate. Variance inflation factors were calculated to ensure
that collinear covariates were not co-modeled. All calculations
were performed using Intercooled Stata 12 (StataCorp, College
Station, TX). A two-tailed a of 0.05 was used throughout.
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Results
Among the 176 RA participants with interpretable lung CT
scans, 56 (32%) had antibodies against PAD4; however, only 19
(11%) had anti-PAD3/4XR. Participant characteristics according
to antibody status are summarized in Table 1. Compared with
individuals negative for anti-PAD, those with anti-PAD3/4XR
were slightly older and less likely to be a current smoker, with
trends to significance for both. Those with anti-PAD3/4XR had a
median disease duration 13 years greater than those with no anti-
PAD (p,0.001) and were significantly more likely to be
seropositive for RF or CCP2 compared with both the groups
with no anti-PAD and those with anti-PAD4 not cross-reactive
with PAD3, although associations with the individual autoanti-
bodies were not as strong. As previously published [17], those with
anti-PAD3/4XR had a significantly higher total SHS score
compared with the other groups. Anti-PAD3/4XR was not
associated with RA disease activity measures or treatments.
Anti-PAD3/4XR was Associated with CT-ILD in
Unadjusted Analyses
Pulmonary outcomes according to antibody status are summa-
rized in Table 2. Any ILD was observed in 58 participants (33%),
among whom 22 (38%) demonstrated a predominant radiographic
ILD pattern of GGO and 36 (62%) demonstrated R/TB/HC.
The median ILD score was 0, with a range of 0–10 units. The
median emphysema score was also 0, and ranged from 0–6.
Among the 158 patients with PFTs, 44 (28%) had any
abnormality, with 30 (21%) demonstrating restriction or impaired
diffusion. Among the 168 patients with assessment of respiratory
symptoms, 69 (41%) reported any symptoms, with a median
number of symptoms of 0 (range 0–4).
For univariate comparisons of pulmonary outcomes according
to antibody status, the prevalence of any ILD was more than
double among those with anti-PAD3/4XR compared with the
group with no anti-PAD and the group with anti-PAD4 that did
not cross-react with PAD3 (both comparisons p,0.05). The
prevalence of both GGO and R/TB/HC was also higher among
those with anti-PAD3/4XR compared with the other antibody
groups. However, anti-PAD3/4XR was not associated with PFT
abnormalities, nor the presence or number of respiratory
symptoms.
RA Characteristics were Associated with Radiographic ILD
The associations of participant characteristics with the presence
of any ILD features on CT (i.e. an ILD score.0) are summarized
Table 1. Patient Characteristics According to PAD3/4 Cross-Reactive Antibody Status.
Characteristic Total (n = 176) No anti-PAD (n=120) Anti-PAD4 only (n =37) Anti-PAD3/4XR (n=19) p-value*
Age, years 5969 5968 5869 6267 0.093
Male, n (%) 71 (40) 43 (36) 21 (57) 8 (42) 0.60
White, n (%) 152 (86) 101 (84) 35 (95) 16 (84) 0.99
Any college, n (%) 133 (76) 86 (72) 31 (84) 16 (84) 0.25
Ever smoking, n (%) 105 (60) 80 (67) 16 (43) 10 (53) 0.23
Current smoking, n (%) 20 (11) 19 (16) 2 (5) 0 (0) 0.075
Reported lung disease (n = 168), n (%) 27 (16) 22 (19) 4 (12) 1 (6) 0.30
RA duration, years 8 (4–17) 7 (4–12) 15 (7–23) 20 (11–28) ,0.001
RF or CCP2 seropositivity, n (%) 137 (78) 87 (73) 33 (89) 18 (95) 0.043
RF seropositivity, n (%) 114 (65) 73 (61) 26 (70) 15 (79) 0.20
CCP2 seropositivity, n (%) 122 (70) 76 (64) 31 (84) 15 (79) 0.30
Any shared epitope alleles, n (%) 122 (70) 79 (67) 30 (81) 14 (74) 0.79
DAS28-CRP 3.7 (2.9–4.4) 3.6 (2.9–4.3) 3.5 (2.8–4.5) 3.8 (3.3–4.3) 0.68
CRP, mg/L 2.4 (1.1–7.7) 2.1 (1.0–7.1) 3.5 (1.5–9.5) 2.0 (1.6–5.4) 0.65
IL-6, pg/mL 3.7 (1.8–7.8) 3.6 (1.7–8.1) 3.9 (1.8–6.3) 3.7 (2.4–9.0) 0.24
Total SHS 8 (1–37) 5 (0–19) 12 (2–43) 56 (14–132) ,0.001
Pain (100 mm VAS) 21 (9–41) 21 (8–40) 23 (10–41) 20 (5–47) 0.71
HAQ-DI (0–3) 0.63 (0.12–1.25) 0.63 (0.12–1.25) 0.75 (0.12–1.25) 0.75 (0–1.88) 0.73
Current prednisone, n (%) 67 (38) 45 (38) 13 (35) 9 (47) 0.41
Current non-biologic DMARDs, n (%) 150 (86) 100 (84) 34 (92) 16 (84) 0.99
Methotrexate, n (%) 114 (65) 79 (66) 22 (59) 13 (68) 0.83
Leflunomide, n (%) 19 (11) 11 (9) 5 (14) 3 (16) 0.41
Current biologic DMARDs, n (%) 81 (46) 55 (46) 17 (46) 10 (53) 0.63
TNF inhibitors, n (%) 78 (45) 52 (44) 17 (46) 10 (53) 0.62
Number of failed DMARDs 1 (0–2) 1 (0–2) 1 (0–3) 2 (0–2) 0.75
Values are mean 6 standard deviation or median (interquartile range) unless otherwise noted.
*p-values are for the comparison of the no anti-PAD vs. anti-PAD3/4XR groups.
PAD=peptidyl-arginine deiminase; anti-PAD3/4XR = anti-PAD3/4 Cross-Reactive antibodies; RA = rheumatoid arthritis; RF = rheumatoid factor; CCP2 = 2nd generation
anti-cyclic citrullinated peptide antibody; DAS= disease activity score; CRP =C-reactive protein; IL = interleukin; SHS = Total modified Sharp-van der Heijde Score;
HAQ=Health Assessment Questionnaire Disability Index; TNF = tumor necrosis factor; DMARD=disease modifying anti-rheumatic drug.
doi:10.1371/journal.pone.0098794.t001
PAD3/4 Cross-Reactive Antibodies and ILD in RA
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e98794
in Table 3. Those with any ILD features on CT tended to be older
than those without ILD and were more likely to be male (both with
trends to significance). Any ILD was strongly associated with both
current and past smoking, but not with reported lung disease.
Those with any ILD were significantly more likely to be
seropositive for RF or CCP2 and had a higher median circulating
IL-6 level. Trends to significance were noted for higher total SHS
and HAQ among those with vs. without ILD. Those with ILD
were also significantly more likely to be treated with prednisone
and current biologics, most of which were TNF inhibitors. ILD
was not associated with methotrexate or leflunomide use, or the
number of failed DMARDs. As expected, those with ILD were
significantly more likely to have PFT restriction or impaired
diffusion and report respiratory symptoms compared with those
without ILD.
Anti-PAD3/4XR Remained Associated with Any ILD After
Adjustment
Crude and adjusted associations of anti-PAD3/4XR with
pulmonary outcomes are summarized in Figure 1. After adjusting
for characteristics associated with either anti-PAD3/4XR or any
ILD, anti-PAD3/4XR remained significantly associated with any-
ILD compared with those with no anti-PAD or those with anti-
PAD4 that did not cross-react with PAD3 (adjusted OR=7.22 for
the comparison of anti-PAD3/4XR vs. no anti-PAD; p= 0.001).
The Combination of Anti-PAD3/4XR with Smoking was
Highly Associated with Any ILD Features
The individual and combined associations of anti-PAD3/4XR
and ever smoking with any ILD are depicted in Figure 2. Before
adjustment, only 16% of participants who were anti-PAD3/4XR
negative and had never smoked had any ILD features on CT. The
prevalence of any ILD was higher among those with either
characteristic, and the magnitude of the association was similar for
never smokers with anti-PAD3/4XR vs. ever smokers without the
antibody. However, 90% of ever smokers seropositive for anti-
PAD3/4XR demonstrated any features of ILD. The prevalence
remained significantly higher for this group compared with the
other groups after adjustment, resulting in an adjusted OR of 61.4
for the comparison of any ILD for ever smokers with anti-PAD3/
4XR compared with never smokers without the antibody
(p = 0.001).
Adjusted Associations of PAD3/4XR with Other
Pulmonary Outcomes
Associations of anti-PAD3/4XR with other pulmonary out-
comes are summarized in Table 4. Both GGO and R/TB/HC
were significantly higher among RA patients with anti-PAD3/
4XR compared to those negative for the antibody in unadjusted
analyses. However, only the predominant pattern of GGO was
significantly associated after MV adjustment. Additionally after
MV adjustment, anti-PAD3/4XR was associated with a higher
ILD Score when considered as a continuous variable. However,
anti-PAD3/4XR was not associated with any abnormalities on
PFTs or the presence or number of reported respiratory symptoms
in either crude or adjusted analyses.
Discussion
In this first investigation of the relationship between the recently
discovered RA-specific auto-antibody, anti-PAD3/4XR, and
radiographic ILD, we detected a robust association for both the
presence and extent of RA-ILD among patients with anti-PAD3/
4XR compared with patients with no anti-PAD antibodies and
even among those with anti-PAD4 antibodies that did not cross-
react with PAD3. The associations were not diminished in
magnitude under various relevant MV adjustment scenarios.
Notably, the combination of anti-PAD3/4XR with a history of
smoking was particularly robust in its association with RA-ILD,
with a synergistic interaction suggested.
The etiopathology of RA-ILD is poorly understood. Adding to
the complexity is heterogeneity in ILD histopathology and the
high prevalence of asymptomatic disease [6]. However, in the
setting of clinical symptoms the disease can be a severe and
frequently lethal consequence of RA [1,4]. Citrullination of lung
proteins may contribute to the pathogenesis of RA-ILD. Fibroblast
and lymphocyte migration through the pulmonary extracellular
matrix to areas of damage, as well as cellular differentiation and
activation, are dependent on interactions between matrix and cell
surface proteins that are highly regulated [28–30]. Citrullination of
key matrix proteins, therefore, could result in aberrant cellular
migration, differentiation, and activation resulting in abnormal
Table 2. Pulmonary Outcomes According to PAD3/4 Cross-Reactive Antibody Status.







Any ILD, n (%) 58 (33) 35 (29) 10 (27) 13 (68) 0.001
Any GGO, n (%) 22 (13) 11 (10) 6 (16) 5 (28) 0.047
Any R/TB/HC, n (%) 36 (22) 21 (19) 8 (22) 7 (39) 0.045
ILD Score, units (0–32) 0 (0–2; range 0–10) 0 (0–2; range 0–6) 0 (0–2; range 0–10) 2 (0–2; range 0–10) 0.020
Emphysema score, units (0–32) 0 (0–0; range 0–6) 0 (0–0; range 0–6) 0 (0–0; range 0–4) 0 (0–0; range 0–2) 0.77
Any PFT Abnormality (n = 158), n (%) 44 (28) 33 (29) 9 (29) 2 (13) 0.23
Any PFT Restriction or Impaired Diffusion, n (%) 30 (21) 21 (22) 8 (27) 1 (8) 0.46
Any respiratory symptoms (n = 168), n (%) 69 (41) 47 (40) 13 (38) 9 (53) 0.43
Number of respiratory symptoms 0 (0–1; range 0–4) 0 (0–1; range 0–4) 0 (0–2; range 0–4) 1 (0–1; range 0–3) 0.55
Values are median (interquartile range) unless otherwise noted.
*p-values are for the comparison of the no anti-PAD vs. anti-PAD3/4XR groups.
PAD=peptidyl-arginine deiminase; anti-PAD3/4XR = anti-PAD3/4 Cross-Reactive antibodies; RA = rheumatoid arthritis; ILD = interstitial lung disease; GGO=ground glass
opacification; R/TB/HC = reticulation/traction bronchiectasis/honeycombing; PFT = pulmonary function testing; Impaired Diff = impaired diffusion.
doi:10.1371/journal.pone.0098794.t002
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tissue repair, ectopic fibrosis, and dysregulated inflammation. For
example, attachment and spreading of fibroblasts was impaired on
plates coated with citrullinated fibronectin compared with non-
citrullinated fibronectin [31]. This mechanism may not be
exclusive to RA, as the presence of citrullinated proteins has been
detected in the tissue targets of several autoimmune conditions,
including the lungs of non-RA patients with ILD [13,14]. An
additional possibility is that citrullinated proteins in the lung are
targets for ACPA, an interaction that may drive ILD. This
possibility is supported by recent evidence for the presence of
ACPA in the sputum of RA patients [32]. However, at present,
any speculative mechanistic links between citrullinated proteins in
the lung, ACPA generation and pathogenesis, and ILD remain to
be elucidated.
While citrullination of lung proteins may contribute to the
pathogenesis of ILD, physiologic barriers limiting PAD activity
may have evolved to regulate such pathologic citrullination. For
one, the calcium threshold for PAD catalytic activity generally
exceeds levels attainable extra-cellularly. In vitro experiments
typically use 5–10 mM calcium concentrations for maximal
PAD activity, whereas in vivo extra-cellular levels typically do not
exceed 1.5 mM [33]. Recently [17], we showed that anti-PAD3/
4XR antibodies increased the sensitivity of PAD4 to calcium
allowing efficient citrullination in the context of physiologic
calcium concentrations. From the same report, anti-PAD3/4XR
reacted with PAD4 at a key calcium binding site that is also
involved in protein-protein interactions, suggesting that the
antibody may create a permissive environment for calcium
activated catalysis. Therefore, the analyses presented here provide
a circumstantial link between a disease manifestation in which
aberrant citrullination may play a pathogenic role (i.e. ILD) and
the mechanism by which citrullination may be facilitated (i.e. anti-
PAD3/4XR).
Smoking is a well-established risk factor for both RA [34] and
ILD [35], and, as confirmed among the cohort reported here, RA
patients with a history of smoking were more likely to have
radiographic ILD. Additionally, compared with non-smokers,
smokers had higher levels of PAD2 in the bronchial mucosa, but
Table 3. Patient Characteristics According to the Presence of CT-ILD Features.
Characteristic No ILD (n=118) Any ILD (n =58) p-value
Age, years 5868 6169 0.071
Male, n (%) 43 (36) 29 (50) 0.085
White, n (%) 101 (86) 51 (88) 0.67
Any college, n (%) 87 (74) 46 (79) 0.42
Ever smoking, n (%) 62 (53) 44 (76) 0.003
Current smoking, n (%) 7 (6) 14 (24) ,0.001
Reported lung disease (n = 168), n (%) 19 (17) 8 (14) 0.66
RA duration, years 8 (4–16) 8 (5–19) 0.22
RF or CCP2 seropositivity, n (%) 86 (73) 52 (90) 0.011
RF seropositivity, n (%) 71 (60) 43 (75) 0.047
CCP2 seropositivity, n (%) 73 (62) 49 (86) 0.001
Any shared epitope alleles, n (%) 80 (68) 43 (75) 0.34
DAS28-CRP 3.5 (2.8–4.3) 3.8 (3.2–4.5) 0.12
CRP, mg/L 2.3 (1.0–7.2) 3.5 (1.2–9.3) 0.58
IL-6, pg/mL 3.0 (1.6–7.0) 4.5 (2.3–9.5) 0.029
Total SHS 6 (0–26) 12 (2–55) 0.074
Pain (100 mm VAS) 19 (10–40) 24 (8–47) 0.52
HAQ-DI (0–3) 0.62 (0.12–1.25) 0.75 (0.25–1.50) 0.083
Current prednisone, n (%) 37 (31) 30 (52) 0.009
Current non-biologic DMARDs, n (%) 103 (88) 47 (81) 0.21
Methotrexate, n (%) 81 (69) 33 (57) 0.13
Leflunomide, n (%) 11 (9) 8 (14) 0.37
Current biologic DMARDs, n (%) 48 (41) 34 (59) 0.028
TNF inhibitors, n (%) 46 (39) 33 (57) 0.028
Number of failed DMARDs 1 (0–2) 1 (0–2) 0.80
Any PFT Abnormality (n = 158), n (%) 22 (21) 22 (43) 0.003
Any PFT Restriction or Impaired Diffusion, n (%) 12 (13) 18 (41) ,0.001
Any respiratory symptoms (n = 168), n (%) 40 (36) 29 (52) 0.046
Number of respiratory symptoms 0 (0–1) 1 (0–2) 0.017
Values are mean 6 standard deviation or median (interquartile range) unless otherwise noted.
RA = rheumatoid arthritis; RF = rheumatoid factor; CCP2 = 2nd generation anti-cyclic citrullinated peptide antibody; DAS = disease activity score; CRP = C-reactive protein;
IL = interleukin; SHS= Total modified Sharp-van der Heijde Score; HAQ=Health Assessment Questionnaire Disability Index; TNF = tumor necrosis factor;
DMARD=disease modifying anti-rheumatic drug; ILD = interstitial lung disease; PFT = pulmonary function testing; Impaired Diff = impaired diffusion.
doi:10.1371/journal.pone.0098794.t003
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no difference in the amount of protein citrullination in the same
tissue [14]. In our study, the combined effect of smoking plus anti-
PAD3/4XR was greater than the sum of the individual effects of
either characteristic in isolation, suggesting a possible synergistic
interaction. In this setting, PAD up-regulation conferred by
smoking combined with the enhanced catalytic activity of PAD4
conferred by anti-PAD3/4XR could provide the stimulus for the
enhanced pathogenic effect observed. Based on this circumstantial
evidence, testing of this speculative mechanistic hypothesis is
warranted.
The study has notable strengths and limitations. Among the
strengths, scans were interpreted by the same pulmonary
radiologist with decades of ILD experience, and ILD features
correlated with both PFT abnormalities and respiratory symp-
toms. Among the limitations, cardiac MDCT differs from high-
resolution CT (HRCT) in slice thickness and the lung apices were
not imaged. However, while we may have missed additional ILD
features exclusive to the apices (uncommon for RA-ILD), our
findings are internally consistent since the same techniques were
used for all patients. Owing to the characteristics of the cohort, our
findings may only be generalizable to RA patients .45 years of
age without prior cardiovascular events, and, notably, there were
few patients with severe RA-ILD included. Additionally, the
primary comparisons were cross-sectional, limiting any ability to
establish temporality in the associations. Additional longitudinal
work is underway exploring the temporal relationship between
emergence of anti-PAD3/4XR over the time-course of RA and
incident RA-ILD.
In summary, anti-PAD3/4XR seropositivity was detected in a
subset of RA patients with longer standing, seropositive, destruc-
tive disease. Independent of these features, the presence of anti-
PAD3/4XR remained highly associated with the presence and
extent of ILD, assessed by CT scanning. Interestingly, the
Figure 1. The Presence of anti-PAD3/4 Cross-reactive Antibod-
ies was Associated with Radiographic RA-ILD. The cohort was
grouped based on the presence of anti-PAD3/4XR antibodies (closed
square), anti-PAD4 antibodies that did not cross-react with PAD3
(closed diamond), or neither reactivity (open circle). The prevalence of
any ILD was more than double among those with anti-PAD3/4XR
compared with those with anti-PAD4 alone or those with neither
reactivity in both crude (left) and adjusted (right) analyses. Average
probabilities and 95% confidence intervals are depicted. Associations
adjusted for age, gender, current and past smoking, rheumatoid factor
and CCP2 seropositivity, DAS28, current use of biologics and
prednisone, RA duration, and total Sharp-van der Heijde Score.
doi:10.1371/journal.pone.0098794.g001
Figure 2. The Combined Effects of anti-PAD3/4 Cross-reactive Antibodies and Smoking Were Robust Indicators of Radiographic
RA-ILD. The cohort was grouped based on the presence of anti-PAD3/4XR (closed markers) and history of ever smoking (i.e. current or former
smokers). The association of anti-PAD3/4XR with ILD was stronger among ever smokers compared to never smokers in both crude (Panel A) and
adjusted (Panel B) analyses. Average probabilities and 95% confidence intervals are depicted. Panel B associations adjusted for age, gender,
rheumatoid factor and CCP2 seropositivity, DAS28, current use of methotrexate and prednisone, RA duration, and total Sharp-van der Heijde Score.
doi:10.1371/journal.pone.0098794.g002
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combination of smoking history with anti-PAD3/4 antibody status
was associated with a frequency of ILD to a greater extent than
expected from the mere addition of their separate effects,
suggesting a synergistic interaction. With additional investigation,
these novel findings have potential implications for both under-
standing the mechanisms underlying the pathogenesis of RA-ILD
and for predicting which RA patients are at risk for developing this
potentially life-threatening RA extra-articular manifestation.
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